Bio-Rad Laboratories, Inc.
Bear Case (25th pct.)
-40.0% vs price
Base Case (Median)
-27.1% vs price
Bull Case (75th pct.)
-16.7% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $201.16 | -43.4% | High (40%) |
| PE Comparable | $183.60 | -48.3% | Medium (25%) |
| Growth Trajectory DCF | $325.96 | -8.2% | Medium (20%) |
| Graham Number | $225.28 | -36.6% | Medium (40%) |
| EV/EBITDA | $458.46 | 29.1% | Medium (20%) |
| EV/FCF | $259.03 | -27.1% | Medium (20%) |
| Earnings Power Value | $265.99 | -25.1% | Medium (50%) |
Based on 7 out of 8 methods, BIO appears overvalued at the current price of $355.23. The base case fair value of $259.03 implies 27.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.